A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Amphastar Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 24,600 shares of AMPH stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,600
Previous 7,400 232.43%
Holding current value
$1.12 Million
Previous $296,000 303.04%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$36.99 - $50.09 $4.73 Million - $6.41 Million
-127,914 Reduced 48.61%
135,237 $6.56 Million
Q2 2024

Aug 14, 2024

BUY
$38.65 - $43.48 $7.55 Million - $8.5 Million
195,454 Added 288.72%
263,151 $10.5 Million
Q1 2024

May 15, 2024

SELL
$42.85 - $63.45 $2.08 Million - $3.08 Million
-48,502 Reduced 41.74%
67,697 $2.97 Million
Q4 2023

Feb 14, 2024

SELL
$44.49 - $62.93 $556,836 - $787,631
-12,516 Reduced 9.72%
116,199 $7.19 Million
Q3 2023

Nov 14, 2023

SELL
$45.51 - $65.0 $2.24 Million - $3.2 Million
-49,235 Reduced 27.67%
128,715 $5.92 Million
Q2 2023

Aug 14, 2023

BUY
$35.77 - $58.38 $5.24 Million - $8.56 Million
146,609 Added 467.79%
177,950 $10.2 Million
Q1 2023

May 15, 2023

SELL
$27.99 - $37.92 $312,536 - $423,414
-11,166 Reduced 26.27%
31,341 $1.18 Million
Q4 2022

Feb 14, 2023

SELL
$27.93 - $31.27 $3.71 Million - $4.15 Million
-132,758 Reduced 75.75%
42,507 $1.19 Million
Q3 2022

Nov 14, 2022

BUY
$27.56 - $37.75 $3.69 Million - $5.05 Million
133,867 Added 323.37%
175,265 $4.93 Million
Q2 2022

Aug 15, 2022

SELL
$29.79 - $42.29 $5.85 Million - $8.31 Million
-196,485 Reduced 82.6%
41,398 $1.44 Million
Q1 2022

May 16, 2022

BUY
$22.96 - $36.45 $559,328 - $887,958
24,361 Added 11.41%
237,883 $8.54 Million
Q4 2021

Feb 14, 2022

BUY
$18.14 - $23.29 $3.87 Million - $4.97 Million
213,522 New
213,522 $4.97 Million
Q3 2021

Nov 15, 2021

SELL
$17.83 - $21.49 $434,570 - $523,775
-24,373 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$17.11 - $20.92 $257,608 - $314,971
-15,056 Reduced 38.19%
24,373 $491,000
Q1 2021

May 17, 2021

SELL
$17.21 - $20.65 $528,501 - $634,140
-30,709 Reduced 43.78%
39,429 $722,000
Q4 2020

Feb 16, 2021

BUY
$17.76 - $21.24 $287,072 - $343,323
16,164 Added 29.95%
70,138 $1.41 Million
Q3 2020

Nov 16, 2020

BUY
$17.99 - $22.22 $292,049 - $360,719
16,234 Added 43.02%
53,974 $1.01 Million
Q2 2020

Aug 14, 2020

SELL
$14.25 - $22.46 $690,768 - $1.09 Million
-48,475 Reduced 56.23%
37,740 $848,000
Q1 2020

May 15, 2020

BUY
$12.66 - $20.08 $1.09 Million - $1.73 Million
86,215 New
86,215 $1.28 Million
Q4 2019

Feb 14, 2020

SELL
$17.07 - $20.64 $2.25 Million - $2.73 Million
-132,053 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$19.12 - $22.62 $1.43 Million - $1.69 Million
74,767 Added 130.52%
132,053 $2.62 Million
Q2 2019

Aug 14, 2019

BUY
$18.92 - $22.96 $815,943 - $990,172
43,126 Added 304.56%
57,286 $1.21 Million
Q1 2019

May 15, 2019

SELL
$19.46 - $25.28 $347,438 - $451,349
-17,854 Reduced 55.77%
14,160 $0
Q4 2018

Feb 14, 2019

SELL
$17.72 - $22.51 $38,381 - $48,756
-2,166 Reduced 6.34%
32,014 $637,000
Q1 2018

May 11, 2018

BUY
$17.23 - $20.35 $588,921 - $695,563
34,180 New
34,180 $641,000

Others Institutions Holding AMPH

About Amphastar Pharmaceuticals, Inc.


  • Ticker AMPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,015,200
  • Market Cap $2.23B
  • Description
  • Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-count...
More about AMPH
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.